Cammarata-Scalisi F, Capolino R, Magliozzi M, Novelli A, Galeotti A, Callea M

Language: Spanish
References: 15
Page: 567-571
PDF size: 142.56 Kb.

ABSTRACT

Marfan syndrome ([MS], OMIM 154700) is a connective tissue disorder that exhibits an autosomal dominant pattern of inheritance, whose clinical characteristics can affect multiple systems or organs in a variable way. It is caused by mutations in the FBN1 gene (OMIM 134797) located at 15q21.1. Neonatal MS is an uncommon variety of the entity associated with missense mutation between exons 23-33 and truncating mutations, exhibits a more severe phenotype and high percentage of mortality in the first years of life. The case of male adolescent with neonatal MS and missense mutation (c.3037G> A; p.Gly225Arg) in exon 24 of the FBN1 gene is presented. Given these findings, interfamilial phenotype variation, the early interdisciplinary medical evaluation necessary for the management of possible complications, as well as the appropriate family genetic counseling were studied.

REFERENCES

1. Aubart M, Gazal S, Arnaud P, Benarroch L, Gross MS, Buratti J, et al. Association of modifiers and other genetic factors explain Marfan syndrome clinical variability. Eur J Hum Genet. 2018; 26(12): 1759-72.

2. Sandvik GF, Vanem TT, Rand-Hendriksen S, Cholidis S, Saethre M, Drolsum L. Ten-year reinvestigation of ocular manifestations in Marfan syndrome. Clin Exp Ophthalmol. 2019; 47(2): 212-8.

3. Handisides JC, Hollenbeck-Pringle D, Uzark K, Trachtenberg FL, Pemberton VL, Atz TW, et al. Health-related quality of life in children and young adults with Marfan syndrome. J Pediatr. 2019; 204: 250-255.e1.

4. Teixido-Tura G, Forteza A, Rodríguez-Palomares J, González Mirelis J, Gutiérrez L, Sánchez V, et al. Losartan versus Atenolol for prevention of aortic dilation in patients with Marfan syndrome. J Am Coll Cardiol. 2018; 72(14): 1613-8.

5. Isselbacher EM. Losartan for the treatment of Marfan syndrome: Hope Fades. J Am Coll Cardiol. 2018; 72(14): 1619-21.

6. Groth KA, Stochholm K, Hove H, Andersen NH, Gravholt CH. Causes of mortality in the Marfan syndrome (from a Nationwide Register Study). Am J Cardiol. 2018; 122(7): 1231-5.

7. Kuruvilla SE, Welch S, Ng Y. Microcornea and bilateral ectopia lentis in an infant: unusual severe ocular presentation of neonatal Marfan syndrome. J AAPOS. 2019; 23(2): 107-8.

8. Solé-Ribalta A, Rodríguez-Fanjul X, Carretero-Bellon JM, Pascual-Sala C, Martorell-Sampol L, Bobillo-Pérez S, et al. Neonatal Marfan syndrome: a rare, severe, and life-threatening genetic disease. J Pediatr. 2019; 211: 221-221.e2.

9. Liu LH, Lin SM, Lin DS, Chen MR. Losartan in combination with propranolol slows the aortic root dilatation in neonatal Marfan syndrome. Pediatr Neonatol. 2018; 59(2): 211-3.

10. Carande EJ, Bilton SJ, Adwani S. A case of neonatal Marfan syndrome: a management conundrum and the role of a multidisciplinary team. Case Rep Pediatr. 2017; 2017: 8952428.

11. Peng Q, Deng Y, Yang Y, Liu H. A novel fibrillin-1 gene missense mutation associated with neonatal Marfan syndrome: a case report and review of the mutation spectrum. BMC Pediatr. 2016; 16: 60.

12. Heo JS, Song JY, Choi EY, Kim EH, Kim JH, Park SE, et al. Atypical neonatal Marfan syndrome with p.Glu1073Lys mutation of FBN1: the first case in Korea. J Korean Med Sci. 2017; 32(1): 1-3.

13. Callea M, Willoughby CE, Cammarata-Scalisi F, Giovannoni I, Vinciguerra A, Yavuz I, et al. A c.3037G>A mutation in FBN1 gene causing Marfan syndrome with an atypically severe phenotype. Invest Clin. 2017; 58(1): 70-8.

14. Nijbroek G, Sood S, McIntosh I, Francomano CA, Bull E, Pereira L, et al. Fifteen novel FBN1 mutations causing Marfan syndrome detected by heteroduplex analysis of genomic amplicons. Am J Hum Genet. 1995; 57(1): 8-21.

15. Tiecke F, Katzke S, Booms P, Robinson PN, Neumann L, Godfrey M, et al. Classic, atypically severe and neonatal Marfan syndrome: twelve mutations and genotype-phenotype correlations in FBN1 exons 24-40. Eur J Hum Genet. 2001; 9(1): 13-21.